By Theo Smart and Javid Syed A TAG-sponsored forum in South Africa brought together scientists, policy makers, and community activists to discuss multidrug resistant and extensively drug resistant TB and HIV and to identify steps to address the growing crisis.…
Scientists at conference examine barriers to curing HIV infection. TAG proposes a workshop in 2008 to move these efforts forward. The HIV persistence workshop is a biannual event held on the small Caribbean island of St. Maarten. The goal of…
New Surveillance Networks Needed By Tracy Swan Recent outbreaks of acute hepatitis C virus (HCV) among HIV-positive men who have sex with men (MSM) have been reported in England, France, Germany, Holland, and the United States. Many of these cases…
In March 2007, a group of community activists, many living with HIV and hepatitis C virus (HCV), gathered with researchers, doctors, regulators, and representatives from Abbott, Roche, Schering, and Tibotec, in Sitges, Spain, at a meeting held by the European…
Drug Company $ Million Change From 2005 Notes Truvada Gilead 1,194 +210% Kaletra Abbott 1,135 +13% Combivir GlaxoSmithKline 977 -8% Reyataz Bristol-Myers Squibb 931 +34% Sustiva Bristol-Myers Squibb 791 +16% Includes $76 million related to Atripla sales Viread Gilead 689…
More Than Just Markers By Richard Jefferys "... no longer solely of interest to academic immunologists ..." At the recent International AIDS Society conference in Sydney, Mike Lederman reminded attendees that abnormally high levels of immune activation were described in the first…
By Richard Jefferys The biggest obstacle to understanding how HIV causes immune damage is the complexity of the human immune system, a vast collection of different cells and tissues that typically work together in concert to protect against disease. HIV…
As this issue went to press, a paper appeared from Daniel Douek and colleagues reporting data which, the authors argue, further supports the model of HIV pathogenesis outlined in their Nature Immunology review. Douek's group had previously speculated that one…
By Rob Camp Tibotec's clinical development program for the protease inhibitor darunavir (Prezista, TMC114) delivered the drug to market several months ahead of schedule. But even as it began shipping to pharmacies around the country one nagging uncertainty remained: Would…